MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202611090079 A) filed by Bhupendra S. Ahirrao; Ms. Gaytri R. Waykar; Ms. Aditya R. Sonawane; Dr. Jeevan R. Rajguru; Mr. Rohit R. Doke; Mr. Nitesh Balaji Awarde; and Mr. Shubham Pitambar Mahale on July 24, 2026, for Stimuli-Responsive Nanocarrier-Based Composition For Targeted Delivery Of Anti-Cancer Agents To Breast Tumor Cells And Method Thereof.
Inventors include Bhupendra S. Ahirrao; Ms. Gaytri R. Waykar; Ms. Aditya R. Sonawane; Dr. Jeevan R. Rajguru; Mr. Rohit R. Doke; Mr. Nitesh Balaji Awarde; and Mr. Shubham Pitambar Mahale.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: [043] The present invention relates to a stimuli-responsive nanocarrier-based pharmaceutical composition for targeted delivery of anti-cancer agents to breast tumor cells. The composition comprises biodegradable nanoparticles encapsulating one or more therapeutic agents and functionalized with breast tumor-targeting ligands capable of promoting receptor-mediated cellular uptake. The nanocarrier incorporates stimuli-responsive mechanisms that selectively release the therapeutic payload in response to tumor-associated physiological conditions including acidic pH, elevated glutathione concentration, reactive oxygen species, hypoxia, or tumor-associated enzymes. The invention further provides methods for preparation and administration of the composition. The disclosed system improves tumor-specific drug accumulation, enhances intracellular delivery, minimizes systemic toxicity, prolongs circulation time, and increases therapeutic efficacy in breast cancer treatment while providing a scalable and pharmaceutically acceptable targeted drug delivery platform. Accompanied Drawing [FIGS. 1-2]
Disclaimer: Curated by HT Syndication.
